Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBRACE: Halaven vs Physician's Choice in Metastatic Breast Cancer
NCT00388726Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2006
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of eribulin in breast cancer (2 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Overall Survival. Started Nov 2006; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00388726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00388726.